Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus SELENIUM SULFIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus SELENIUM SULFIDE.
FULVICIN-U/F vs SELENIUM SULFIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Category C
Category A/B
Antifungal
Antifungal / Antiseborrheic